Squamous cell carcinoma of the head and neck (SCCHN) is one of the six most frequently diagnosed malignancies worldwide. Second/third primary tumors are the main threats to long-term survival once there has been successful treatment of early-stage SCCHN. The anatomy of the head is divided into sites and subsites; tumors at each site have a particular epidemiology, anatomy, natural history, and therapeutic approach. A large number of SCCHN cases arise due to persistent human papillomavirus (HPV) infection. Two vaccines against HPV have been approved in the major markets: Merck & Co.’s Gardasil and GlaxoSmithKline’s Cervarix; however vaccination rates in most markets covered in this report are low with the exception of the United Kingdom. There is currently only one targeted therapy approved for the treatment of SCCHN: cetuximab (Bristol-Myers Squibb/Eli Lilly/Merck KGaA’s Erbitux). Using primary research conducted with expert U.S. and European SCCHN specialists, this report provides a comprehensive analysis of the competitive landscape and market opportunity for SCCHN. It includes a comprehensive analysis of patient populations, current therapies and medical practices, unmet needs, and emerging therapies.